Efficacy of pomalidomide plus low-dose dexamethasone in multiple myeloma patients despite previous use of lenalidomide.

作者
Joe Mikhael,S. Vincent Rajkumar,Vivek Roy,Susan R. Hayman,Rafaël Fonseca,Kristen Detweiler Short,Betsy R LaPlant,K. M. Laumann,Angela A. Dispenzieri,Martha Q. Lacy
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:29 (15_suppl): 8067-8067 被引量:7
标识
DOI:10.1200/jco.2011.29.15_suppl.8067
摘要

8067 Background: Pomalidomide (CC4047 or Pom) is the newest oral immunomodulatory agent. It yields less neuropathy than thalidomide (thal) and less myelosuppression than lenalidomide (len). Pom/dex has demonstrated response rates (>PR) of 63% in relapsed MM (Lacy, JCO 2009) and 32% in len-refractory MM (Lacy, Leukemia 2010) using a 2mg/day dose. The MTD has been determined to be 4 mg/day but the optimal dose has not yet been defined. We report a phase II trial using the Pom 4mg with dex to study its efficacy in patients with prior len. Methods: Patients must have had 1-3 lines of prior therapy (including len). Pom 4mg daily was given orally on days 1–28 (28-day cycle) with oral dex given 40 mg daily on days 1, 8, 15 and 22. All patients received DVT prophylaxis with aspirin 325 mg daily or therapeutic anticoagulation. Results: 61 patients with relapsed MM were enrolled. Median age was 65 years (32-82), and 40 were male. Median time from diagnosis to enrollment was 37 months (1-84). Fifteen (25%) patients had high risk disease as defined by mSMART (mSMART.org). Sixty (98%) patients received prior len, 29 (47%) had bortezomib, 13 (21%) thal, 47 (77%) auto transplant and 3 (5%) allo transplant. Toxicities at least possibly attributed to drug included grade 3/4 anemia (7/0%), grade 3/4 leukopenia (27/2%), grade 3/4 thrombocytopenia (3/2%). Grade 3 non-hematologic toxicities occurred in 18% of patients and included fatigue 5%, thrombosis 5%, hyperglycemia 5% and pneumonia 5% (no grade 4). Grade 1/2 neuropathy occurred in 18/8%, (no grade 3 or 4). Twenty three (38%) patients required dose reductions in dex. Confirmed responses (>PR) were seen in 21 patients (35%), of which 7 (12%) were VGPR, 14 (23%) PR, 8 (13%) MR, 25 (42%) SD and 6 (10%) PD. Median time to response was 1.1 months (0.8-2.8). With a median follow-up 4.1 months, 67% remain progression free, and 97% remain alive. Conclusions: This large phase II demonstrates that Pom/dex is active and very well tolerated in patients who have already been treated with len. Objective response is seen in 48% despite being heavily pre-treated with IMiDs, bortezomib and transplant. This study reconfirms therapeutic benefit for Pom/dex in patients relapsing after other novel therapies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
qweqwe完成签到,获得积分10
1秒前
大狗叫俱乐部天使一号布鲁斯道格完成签到 ,获得积分10
1秒前
动听的妙柏完成签到 ,获得积分10
1秒前
ZQ完成签到,获得积分10
2秒前
zzl完成签到,获得积分20
3秒前
可爱的函函的应助被细心沂采纳,获得10
4秒前
脑洞疼的应助被繁荣的萝莉采纳,获得10
4秒前
4秒前
虾米米0918完成签到 ,获得积分10
5秒前
6秒前
铠甲勇士完成签到,获得积分10
6秒前
可爱的函函的应助被林慧宁采纳,获得10
6秒前
锂离子发布了新的文献求助10
6秒前
7秒前
天天快乐的应助被WGZ1980049314采纳,获得10
7秒前
8秒前
8秒前
9秒前
obcx发布了新的文献求助10
10秒前
11秒前
yuyu发布了新的文献求助10
11秒前
隐形曼青的应助被坚强孤容采纳,获得10
11秒前
zk1438328200完成签到,获得积分10
13秒前
专注的荣轩完成签到,获得积分10
13秒前
luo运俊发布了新的文献求助10
13秒前
13秒前
orixero的应助被刺五加采纳,获得10
13秒前
LpmxRk发布了新的文献求助10
13秒前
科目三的应助被细心沂采纳,获得10
13秒前
李健的小迷弟的应助被CJX采纳,获得10
14秒前
科研顺利发布了新的文献求助10
14秒前
整齐芷文完成签到,获得积分10
15秒前
暴躁的紫青完成签到,获得积分20
16秒前
逐徒发布了新的文献求助10
16秒前
111完成签到,获得积分10
16秒前
钟钟完成签到 ,获得积分10
17秒前
18秒前
科研通AI6.3的应助被孤星采纳,获得10
19秒前
luo运俊完成签到,获得积分10
19秒前
科研通AI6.2的应助被yuyu采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186806
求助须知:如何正确求助?哪些是违规求助? 9575125
关于积分的说明 21839712
捐赠科研通 7784453
什么是DOI,文献DOI怎么找? 3434839
关于科研通互助平台的介绍 2559245
邀请新用户注册赠送积分活动 2481712